In light of recent events in my personal life forcing uncharacteristic delays between posts, I'll review briefly what I've discussed so far before continuing the discussion about the FDA's recent revocation of approval Avastin for treatment of breast cancer.
Now let's look at the players who influenced the FDA's decision to revoke approval of Avastin for breast cancer. The complex process requires a book-length manuscript to fully explain. Rather than abandon my effort, here are the bare bones:
My last post provided an outline of the FDA's approval process. I cringed while writing it, knowing 250 words couldn't capture the investment of time, people and capital.
When I was in practice, after seeing a patient in the hospital I would occasionally write a so-called holding note in the patient's chart. This was a synopsis that indicated I'd return later to complete the evaluation and write a proper admission note.
It was common practice to write a holding note if other patients' urgent needs pulled me away.
